Hemeo Secures $3M Seed Round to Transform Coagulation Therapy with AI-Driven Clinical Support System

Hemeo is excited to announce that we have successfully raised €3,000,000 in our latest round of funding—a crucial milestone that fuels our mission to revolutionize clinical support systems. Based in The Netherlands, our company leverages a thriving innovation ecosystem, collaborating with esteemed partners such as NLC, the European Healthtech Venture Builder, and Philips, where our core technology was initially developed. At Hemeo, we focus on building a state-of-the-art Clinical Support System that predicts coagulation problems using advanced A.I. powered technology. Our innovative algorithms, trained and verified against a robust clinical database comprising over 5,000 patients, enable earlier and highly personalized therapeutic interventions that can fundamentally change patient outcomes in coagulation care. The recently secured funds will be strategically directed towards enhancing our predictive algorithms and expanding our research collaborations with leading academic centres worldwide. These collaborations are pivotal in further validating our coagulation model and ensuring that our A.I. systems meet the highest clinical safety and efficacy standards. Moreover, the investment will enable us to accelerate our product development roadmap and scale up our technological infrastructure, paving the way for more tailored and data-driven approaches in hospital settings and beyond. This funding round reinforces our commitment to bridging the gap between data science and clinical practice and highlights the market’s confidence in our vision. We are proud to drive innovation in healthcare and grateful for the financial support that underscores our potential to transform coagulation risk management. As we enter this new phase of growth, Hemeo remains dedicated to fostering collaborations and pushing the boundaries of what A.I. can achieve in healthcare.